Delayed treatment of HIV linked to greater risk of dementia

Delayed HIV treatment may significantly increase the risk of dementia later in life, according to new research from Kaiser Permanente. The study highlights the critical importance of early diagnosis and prompt initiation of antiretroviral therapy (ART) for individuals living with HIV.

The Link Between HIV Treatment Timing and Dementia

Researchers found that individuals diagnosed with HIV and subsequently treated with ART, but who had a low CD4 count – a measure of immune system strength – at the start of treatment, were more likely to receive a dementia diagnosis years later. This finding, published in the journal Open Forum Infectious Diseases, underscores a previously understood but now more clearly defined connection between immune system health and long-term cognitive well-being.

Did You Know? HIV treatment guidelines have evolved, with a shift from delaying treatment until CD4 counts lowered to recommending immediate ART after diagnosis.

The study followed 21,354 people aged 50 and older on ART for an average of 7 years. Of those, 618 were diagnosed with dementia. Individuals with lower CD4 counts before starting ART faced a 33% greater likelihood of a dementia diagnosis. While improving CD4 counts through treatment reduced this risk, it did not eliminate it entirely.

Understanding the Changing Landscape of HIV Care

The research builds on a growing body of evidence regarding the long-term health implications of HIV. As people with HIV live longer, thanks to advancements in treatment, understanding their risk of age-related chronic diseases becomes increasingly important. Researchers are focused on identifying modifiable factors, such as blood pressure and the timing of ART, that may influence cognitive health.

Expert Insight: This research reinforces the need for a proactive approach to HIV care, emphasizing that early intervention isn’t just about managing the virus, but also about potentially safeguarding long-term cognitive health.

The types of dementia observed in the study were broad, encompassing Alzheimer’s disease, vascular dementia, Parkinson’s dementia, dementia with Lewy bodies, frontotemporal dementia, and other unspecified forms.

Broader Implications for HIV and Aging

A separate study by the same Kaiser Permanente team, published in the journal AIDS, revealed that older adults with HIV had nearly double the rate of dementia compared to their HIV-negative counterparts. Although the risk decreased over time for both groups, it remained elevated for those living with HIV over a 16-year period.

Researchers emphasize the value of utilizing large electronic health datasets, such as those available at Kaiser Permanente, to study relatively uncommon health outcomes like dementia and to identify patterns within diverse populations.

Frequently Asked Questions

What is a CD4 count?

A CD4 count is a measure of the strength of the immune system. Lower CD4 counts indicate a weakened immune system.

What types of dementia were included in the study?

The study included a broad range of dementia diagnoses, including Alzheimer’s disease, vascular dementia, Parkinson’s dementia, dementia with Lewy bodies, frontotemporal dementia, and other or unspecified dementia.

Did improving CD4 counts eliminate the risk of dementia?

While improving CD4 counts after starting ART reduced the increased dementia risk, the study found it did not eliminate it entirely.

What might happen next is that further research could focus on identifying specific interventions to mitigate the risk of dementia in individuals with a history of low CD4 counts prior to ART initiation. Clinicians may also prioritize more frequent cognitive assessments for this patient population. It is also possible that new therapies could emerge to specifically address cognitive decline in people living with HIV.